This is mainly because of the reported weight loss While GLP-1 medications Zepbound and This rapid increase in users of GLP-1 drugs has caused Now, a new study published in Annals of Internal Medicine , reports that among the approximately 1 million new GLP-1 medication users identified between 2011 to 2023, there was a twofold increase in GLP-1 medication users who do not have type 2 diabetes but do have a body mass index (BMI) of 30 killograms per square meter (kg/m 2 ) or greater, and in people with a BMI of 27 to 30 kg/m 2 and an obesity-related The researchers also found that the proportion of users of GLP-1 medications without FDA-approved indications rose from 0.21% in 2019 to 0.37% in 2023
legal help when you need it most
4,6 Efficacy A1C-Lowering Effects: Compared with other oral antihyperglycemic agents, DPP-4 inhibitors are considered to have intermediate glycemic efficacy
How do I send prescriptions
Since January 2023, UK authorities have seized over 900 fake weight-loss pens
June 3, 2025: There are 1,882 GLP-1 claims in the federal MDL, many of which involve Mounjaro